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Background: Tumor expression of estrogen receptor (ER) is an important marker of prognosis, and is predictive of
response to endocrine therapy in breast cancer. Several studies have observed that epigenetic events, such
methylation of cytosines and deacetylation of histones, are involved in the complex mechanisms that regulate
promoter transcription. However, the exact interplay of these factors in transcription activity is not well understood.
In this study, we explored the relationship between ER expression status in tumor tissue samples and the
methylation of the 5′ CpG promoter region of the estrogen receptor gene (ESR1) isolated from free circulating DNA
(fcDNA) in plasma samples from breast cancer patients.
Methods: Patients (n = 110) with non-metastatic breast cancer had analyses performed of ER expression (luminal
phenotype in tumor tissue, by immunohistochemistry method), and the ESR1-DNA methylation status (fcDNA in
plasma, by quantitative methylation specific PCR technique).
Results: Our results showed a significant association between presence of methylated ESR1 in patients with breast
cancer and ER negative status in the tumor tissue (p = 0.0179). There was a trend towards a higher probability of
ESR1-methylation in those phenotypes with poor prognosis i.e. 80% of triple negative patients, 60% of HER2
patients, compared to 28% and 5.9% of patients with better prognosis such as luminal A and luminal B,
respectively.
Conclusion: Silencing, by methylation, of the promoter region of the ESR1 affects the expression of the estrogen
receptor protein in tumors of breast cancer patients; high methylation of ESR1-DNA is associated with estrogen
receptor negative status which, in turn, may be implicated in the patient’s resistance to hormonal treatment in
breast cancer. As such, epigenetic markers in plasma may be of interest as new targets for anticancer therapy,
especially with respect to endocrine treatment.
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Mean age; years (range) 58 (32–88) 12.4
Mean age at menarche;
years (range)
13 (10–17) 1.4






Mean age at first live birth;
years (range)
25 (18–41) 3.9






Breastfeeding; months (range) 6 (1–36) 5.1
SD: standard deviation.
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The therapeutic options indicated for patients with
breast cancer continue to be based, principally, on
clinical-pathology criteria. The incorporation of new im-
munohistochemistry and molecular biology markers into
the diagnosis has advanced the knowledge of potential
markers of prognosis and prediction of response to
endocrine therapy in breast cancer. One of the bio-
markers most used is the expression of estrogen and of
progesterone receptors (ER and PR, respectively) [1].
However, only 2/3 of the patients diagnosed with breast
cancer express ER at diagnosis (ER+), while the other
1/3 of the cases do not express the receptors (ER-), and
which is associated with non-differentiated tumors, with
high cell proliferation index, poor response to endocrine
therapy and poor prognosis [2]. Some tumors which are
ER + at the time of diagnosis become ER- in the course
of the clinical evolution of the disease [3]. Also, 30-40%
of the ER + patients will develop resistance to the anti-
estrogen treatment and which will favor the appearance
of distant metastases, and death.
To date, the molecular bases of the response to endo-
crine therapy are poorly understood. Recent studies have
shown that heterogeneity of response and prediction
of response to chemotherapy and sensitivity to hormone
therapy is based on “molecular portraits” [4,5]. However,
the list of genes implicated in prognosis may or may not
necessarily relate to the clinical results obtained in re-
sponse to treatment [6] and, as such, warrants further
investigation.
To date, methylation of DNA is known as an epigenetic
phenomenon which plays a decisive role in the regulation
of signal translation processes. Under physiological condi-
tions, this epigenetic event influences which genes are ac-
tivated during the process of normal cell differentiation
[7], the maintenance of “genetic imprinting” [8], inactiva-
tion of the X chromosome [9], genetic transcription re-
pression [10] and the suppression of regions of parasite
DNA [11]. However, these epigenetic events, when aber-
rant, have a determining role in the development of malig-
nant tumor processes [12,13] and, as well, the suggestion
is of an involvement in resistance to chemotherapy, radio-
therapy and hormone therapy [14].
ER role is key since up to 1/3 of the patients who do not
express ER (i.e. ER-), rarely respond to hormone treatment
[15]. ER is coded-for by the ESR1 gene located at chromo-
some 6q25.1, the promoter region of which contains a
linked CpG sequence in exon 1. In breast cancer cell lines
such as MCF-7, T47-d and ZR75-1 [16] that express ER
(i.e. ER+) this region is observed to be non-methylated,
and is similar to that occurring in normal tissue. However,
in cells lines from ER- breast cancer, such as MDA-MB-
231, MDA-MB-435, MDA-MB-468, Hs578t and MCF-7/
Adr, methylation is observed in >50% of cases [17]. Hence,determining the methylation status of the promoter region
of the ERS1 could be critical since it represents one of the
mechanisms by which the loss of ER expression is associ-
ated with breast cancer diagnosis. Blocking this process of
methylation could be important since this could lead to
patients who are resistant to hormone treatment becom-
ing sensitive to hormone treatment [18].
Based on the literature, as well as on the experience in
our own research group [19-21], we designed the
present study to assess whether ER- expression in tumor
tissue correlates with methylated status of the ESR1 in
serum i.e. a mechanism of gene silencing that can ex-
plain, at least in part, the lack of hormone therapy effi-
cacy in breast cancer. Also, we sought insight into
fcDNA methylation and tumor phenotypes: Luminal A
(LA), Luminal B (LB), Triple negative (TN) and Her2 +.
Methods
Study population
A total of 110 patients diagnosed as having non-metastatic
breast cancer in the Hospital Universitario Virgen de las
Nieves de Granada (Spain) were included in the study.
Patient characteristics are summarized in Table 1. The
study was approved by the Institutional Ethics Committee
of the Hospital Universitario Virgen de las Nieves de
Granada, and written informed consent was obtained from
all study participants.
Collection and processing of samples and DNA preparation
Blood samples (10 ml) were taken by venipuncture from
all the study patients on introduction into the study and
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samples were collected into EDTA Vacutainer® tubes and
coded before processing to ensure blinding with respect
to sample provenance. The samples were transported at
room temperature to the laboratory, centrifuged at
2000 g for 10 min at room temperature, the plasma ob-
tained was distributed in 1 ml aliquots into 1 ml crio-
tubes, and stored at -80°C until needed for processing.
- DNA isolation: DNA from plasma samples (2 ml per
column) was obtained using QIAmp DNA Blood kit
(QIAGEN Inc., CA) according to manufacturer’s recom-
mendations. A final elution volume was 200 μl and the
extracted DNA was quantified spectrophotometrically.
The amount of DNA recovered, measured as μg/sample,
was 0.431 ± 0.019 (mean value ± standard error of the
mean). The fcDNA samples were stored at −80°C until
needed for analysis.
Quantitative Methylation Specific (QMS) polymerase chain
reaction (PCR) analysis
- DNA bisulfite modification: Identical DNA sequences
that differ only in methylation status can be amplified by
means of Quantitative Methylation Specific PCR (QMS-
PCR) [22]. Reagents required for the bisulfite modification
of fcDNA were supplied in the CpGenome™ DNA Modifi-
cation Kit (Intergen, MA). The process was performed ac-
cording to manufacturer’s recommendations. Sufficient
fcDNA can be recovered to perform QMS-PCR from an
amount of starting material as small as 0.001 μg. In brief,
100 μl of extracted fcDNA was treated with sodium bisul-
fite for 16 h, thereby converting all unmethylated cyto-
sines to uracils, but leaving methylcytosines unaltered.
After purification, the fcDNA obtained was dissolved
in 20 μl of TE buffer and the modified DNA was spectro-
photometrically quantified. Efficiency of fcDNA recovery
after bisulfite modification was around 55% (data not
shown). Recovered bisulfite-treated fcDNA (1 μl) was used
in each well for SYBR green reaction. Modified DNA of
standards and samples are stable for at least 2 months
at −80°C. A sample of bisulfite-modified universally-
methylated genomic DNA, (CpGenomeTM Universal
Methylated DNA, Intergen, New York, NY) treated in the
same way as patient samples and the concentration ad-
justed, after modification, to 2 μg/ml (quantified spectro-
photometrically), served as internal standard in preparing
serial dilutions (from 1 to 1/128 with MiliQ water) to con-
struct a standard curve for Real-Time QMS-PCR. Each
multi-well plate contained patient samples, serial dilutions
of completely methylated DNA for constructing calibra-
tion curves, positive controls, and two wells with water
used as negative controls (“blanks”). In all experiments,
correlation coefficients for the calibration curves were
>0.98, slopes ranged from 3.2 to 3.4, and PCR efficiencies
were around 100%.As found by other authors [19,20,23,24], some gene
promoters were frequently observed to have methylated
DNA in the plasma of cancer patients, albeit traces of
methylated DNA may also be found in plasma of pa-
tients without cancer when highly sensitive quantitative
techniques are used. Hence, cut-off points for the ESR1
methylated promoter was established from the receiver
operating characteristics (ROC) curves i.e. selecting
values that gave the maximal likelihood ratio (in current
case the cut-of value was 0.02 relative units) [20]. As-
suming levels of methylation of ESR1 < 0.02 relative
units, “test of methylation (−)”, was indicative of absence
of the disease (physiological) while levels of methylation
of ESR1 > 0.02 relative units measured in the plasma
“test of methylation (+)” was indicative of presence of
breast cancer (pathological level of methylation). Once
the distribution of cases was established in the two
groups as “test of methylation (−)” and “test of methyla-
tion (+)”, the study proceeded to assess whether this
characteristic was associated with the phenotype ER(+)
and ER(−) in tumor tissue.
Using a method developed previously in our group
[20,21], Quantitative Methylation Specific PCR (QMS-
PCR) was performed with the iQ SYBR-Green Supermix
Kit (BioRad Laboratories; Hercules, CA) according to the
manufacturer’s protocol. The sequences of the primers for
ESR1 were selected from previous publications: ESR1
Genebank 2099 location to transcription start Promoter
A [25]. The fluorescence value corresponding to each
sample was converted into relative units of universally
methylated DNA (umDNA; μg/mL) using the corre-
sponding calibration curve adjusted by the software
program of the QMS-PCR equipment. The PCR reac-
tion was conducted in 96-well plates which contained:
patient samples, successive dilutions for the calibration
curve, 2 positive controls, and 2 negative controls or
“blanks” (without DNA). In all cases the correlation co-
efficients for the calibration curves were ≥ 0.98, the lin-
ear slope was between 3.02 and 3.2, and the PCR
efficacy was between 85 and 110%.
Immunohistochemical staining for ER, PR and HER2
expression in tumor tissue
Starting with surgically excised tissue preserved in
formol, tumor pieces were embedded in paraffin and
processed for staining with eosin-hematoxylin. ER and
PR expression were evaluated in tumor tissue using
the DAKO HORIZON automatic processor (Techmate
Horizon). Monoclonal antibody kits were purchased
from the manufacturer (DAKO M 7047 Clone 185 for
ER and DAKO M 3569 Clone 636 for PR) and used
according to the manufacturer’s instructions. Nuclear
staining indicates positive or negative. Positivity is
expressed as intensity of staining and graded as weak (+)
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cells stained. Subsequently, HER2 amplification in the
tumor sample was with the DAKO K5206 kit. In those
cases with HER2 (++), further analysis was with FISH
using the DAKO K 5331, HER FISH PharmDxTM kit
and hybridized in the DAKO HYBRIDIZER.
Statistical methods
The data obtained were analyzed using the following
statistical tests: 1) description of the demographic and
clinical-pathology variables using means, medians, per-
centiles, ranges and standard deviations; 2) relationships
between ER expression in tumor and quantitative speci-
men level of ESR1 methylation using Chi-square (and
Fisher’s exact) test.
Results and discussion
The demographic and clinical-pathology characteristics
of the participants at study entry are summarized in
Tables 1 and 2. The cut-off points for ESR1 methylatedTable 2 Clinico-pathological characteristics of the breast
cancer patients
Characteristic Cases % of
totalN = 110
Histological type
Invasive ductal carcinoma 82 74.5
Invasive lobulillar carcinoma 10 9
Invasive mixed carcinoma 7 6.3
Others 11 10
Histological grade
Grade I 20 18.7
Grade II 40 37.4











Luminal A 39 36.4
Luminal B 22 20.5
Triple Negative 15 14
Her2-neu 10 9.3
Unknown 21 19.6promoter in plasma samples were established from the
ROC curves, selecting values that gave the maximal like-
lihood ratio of 0.02 relative units for ESR1. From our re-
sults previously obtained [20], we assume that levels of
methylation of ESR1 >0.02 relative units are indicative of
the presence of disease (test “+” indicating breast cancer
and pathologic level of methylation ESR1) whereas level
of methylation <0.02 relative units indicating absence of
disease (test “–” indicating no presence of breast cancer
and physiologic level of methylation ESR1). Subsequently
we sought correlations between methylation levels of the
ESR1 promoter in the fcDNA samples and the absence
of transcription and, in turn, with the lack of ER expres-
sion in tumor tissue.
Using Chi-square (and Fisher’s exact) test we studied
the relationship between a positive test value for ESR1-
DNA promoter methylation in plasma sample and ER-
status in excised tumor samples from patients with
breast cancer (p < 0.05). Similarly, we checked for corre-
lations between negative test value for ESR1 vs. ER + in
tumor tissue and observed that the relationship was sta-
tistically significant (p < 0.05). Results obtained showed
an association between presence of methylated ESR1 in
fcDNA from patients with breast cancer and ER- status
in tumor, an observation that would be expected if pro-
moter methylation leads to silencing of gene expression,
and vice versa.
Similarly, we investigated the relationship between the
gene expression silencing mechanism (using methylation
of the ESR1 promoter i.e. epigenetic silencing) and the
luminal phenotype of the tumor tissue; the hypothesis
being that the predominant role of methylation is gene
silencing (i.e. restricted expression) in the tumor. The
Chi-square (and Fisher’s exact) test showed a signifi-
cantly (p < 0.05) higher percentage of ESR1 promoter
methylation in those phenotypes with poorer prognosis
i.e. 80% of the triple negative patients and 60% of pa-
tients with HER2 compared to 28% and 36% of patients
with phenotypes of better prognosis such as luminal A
and luminal B, respectively (Table 3, Figure 1).
Based on these findings, we analyzed whether there
could be subgroups of patients within each luminal
phenotype such that a methylation profile could explain,
at least in part, why some cases develop distant metasta-
ses despite having a good prognostic phenotype. We ob-
served that, within each subgroup segregated with
respect to ESR1 methylation in the fcDNA sample, there
was a tendency towards a lower survival at 4.5 years
of follow-up in each phenotype that had methylated
ESR1 (ESR1 methylation level >0.02) compared to the
subgroup in which the ESR1 methylation level was
<0.02. However, these differences were not statistically
significant, perhaps because of the small number of
cases (Table 4).
Table 3 Percentage ER hypermethylation in relation to tumor phenotype
Test result
Luminal A Luminal B Triple negative HER2(+)
P
n % n % n % n %
(−) ESR1 < 0.02 28 (71%) 14 (64%) 3 (20%) 4 (40%) <0.05
(+) ERS1 > 0.02 11 (28%) 8 (36%) 12 (80%) 6 (60%) <0.05
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in tumor tissue of breast cancer represents one of the
principal prognostic factors of long-term survival, and is
predictive of the disease response to hormone therapy.
As such, the patients with tumors that are ER + are asso-
ciated with a more favorable prognosis and the hormo-
nal treatment of which is based on tamoxifen and/or
aromatase inhibitors. However, in those patients that
present tumors with ER-, the hormone treatment has lit-
tle or no therapeutic value but there is an element of im-
pact on the prognosis of the disease i.e. ER- is associated
more frequently with those cases in which the course of
the disease is more adverse. Around 25% of breast can-
cer patients do not express ER at the time of diagnosis
and, as such, are resistant to hormonal therapy [2]. Also,
in some cases the initial expression of ER + can change
to ER- and negatively impact on the long-term course of
the disease due to loss of sensitivity to the hormonal
treatment [26]. Further research is warranted to explain
this finding of change in phenotype [27].
In our literature search, we did find a few studies that
correlated the epigenetic profile of methylation and its
relationship with ER expression status but no study cor-
relating the methylation with luminal phenotype. There
have been earlier studies that investigated the role of
methylation of various genes in search of independent





























Figure 1 Histogram showing breast cancer subtype of poorer progno
methylation > 0.02 relative units, while those phenotypes with better
promoter methylation is < 0.02 relative units.methylation of the promoter region of the ESR1 gene
has received little attention in relation to the absence of
ER expression in the corresponding tumor. Authors
such as Widschwendter et al. [29] described a significant
relationship (p = 0.015) between the APC methylation
status and hormonal receptor status predictors in pa-
tients with breast cancer. Others studies, such as that by
Yang et al. [30], suggested that, in ER + patients, there
may be a higher frequency of hypermethylation of the
promoter of the Twist gene, while methylation of the
CDH1 gene occurs with higher frequency in patients the
ER- tumors. Recent articles suggest that the hyperme-
thylation of this gene promoter occurs predominantly in
triple negative breast cancer [31]. This hypothesis is con-
tested by other authors [32].
In the present study of cases in which we observed
hypermethylation of the ESR1 promoter in plasma of the
patients with breast cancer, we undertook an analysis of
epigenetic signal silencing of the ESR1 gene in patients
segregated with respect to luminal phenotypes, to the
histopathology of the tumor, and to ER protein expres-
sion in the tumor. We evaluated ESR1-fcDNA methyla-
tion in peripheral plasma in relation to ER expression in
tumor tissues. The results showed that the methylation
of ERS1-fcDNA was correlated significantly with the ab-
sence of ER protein expression in the tumor, and vice




R1-DNA methylation < 0.02 relative units
R1-DNA methylation > 0.02 relative units
sis (TN and Her2) have higher percentage of ESR1-DNA promoter
prognosis (luminal A and luminal B) the percentage of ESR1-DNA
Table 4 Differences in presentation of aberrant ER
methylation within the luminal phenotype subgroups
Phenotype N OS at 5 years P
ER non-methylated
Luminal A 28 93% NS
Luminal B 14 92% NS
Triple Negative 3 80% NS
Her2 4 75% NS
ER methylated
Luminal A 11 82% NS
Luminal B 8 86% NS
Triple negative 12 75% NS
Her2 6 67% NS
OS: overall survival.
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in breast cancer cell lines. Essentially, these authors de-
scribed that the promoter located in exon 1 of the ESR1
gene is observed to be highly methylated in the cell lines
that do not express ER protein and, conversely, is not
methylated in normal breast tissue as well as in the cell
lines of breast cancer that express functioning estrogen
receptors.
With respect to the luminal phenotype and ESR1
methylation status, we observed that, in those cases with
the better prognosis phenotypes (luminal A and luminal
B) the predominant result of the evaluation of ESR1-
fcDNA methylation was negative i.e. there was a correl-
ation between ER expression and better prognosis while,
in the phenotype with poor prognosis (Her2-neu and
triple negative), the evaluation was predominantly posi-
tive (p < 0.05). Further analysis of each luminal pheno-
type with respect to methylated ESR1 >0.02 relative
units versus methylated ESR1 <0.02 relative units,
showed that, within each subgroup, those that presented
methylated ESR1 (and as such not expressing ER recep-
tors) had a tendency towards shorter overall survival
than those with a methylated ESR level < 0.02 relative
units. Hence, it appears that the molecular variant of the
methylated promoter region of the ESR1 gene carries
prognostic information that is additional to the prognos-
tic factors that are currently used in the breast cancer
clinic.
From the above observations, the most relevant of the
results obtained is that methylation, as an epigenetic
event, can be one of the mechanisms implicated in the
non-expression of ER in the tumor. We observed signifi-
cant correlation between ESR1 DNA methylation in
peripheral blood and silencing of ER expression in
the tumor, and vice versa. This finding is of consider-
able interest especially since we observed, as well, thecorrelation between ESR1-fcDNA methylation and the
ER expression in relation to tumor phenotype. The
greater expression of the estrogen receptors in the phe-
notypes that are known to have a better prognosis (LA
and LB) while showing significantly lower levels of ESR1
in peripheral blood. This contrasts with those pheno-
types in which the ER expression is low or not present
which, in turn is associated with poorer prognosis (triple
negative and Her2). The mechanisms involved in the ab-
sence of ER expression are not known, and neither are
the reasons for non-response to hormonal treatment. Of
note, as well, is that tumors that express ER at the time
of diagnosis can cease expressing ER over the time-
course of the disease. Perhaps one of the causal events
in the absence of ER expression (and its negative impact
on the clinical evolution of the disease) is that tumors
expressing ER at the time of diagnosis are methylated. In
studies conducted to date, the known genetic alterations
do not fully explain the processes but, based on the re-
sults from our study, perhaps methylation is the key to
explaining, at least in part, some of the observations.
Also, given that methylation is a reversible event, analyz-
ing this reversibility can be useful in identifying the cru-
cial point in the success, or otherwise, of hormonal
treatment of breast cancer.
Conclusions
Our results indicate that the silencing of gene expression
by methylation of the promoter region of the ESR1 gene
of the estrogen receptor has an important role in the ex-
pression of the protein for which this gene codes (i.e. the
estrogen receptor) in the primary tumor. The methylation
of ESR1 in peripheral bold correlates significantly with
the non-expression of ER in excised tumor tissue. As such,
this measurement may add prognostic value in identifying
luminal phenotypes with poor prognosis and, as well,
those with potentially greater resistance to hormonal
treatment. The protein is absent in ER- tumors when
methylation occurs in the ESR1 promoter, and vice versa.
These data demonstrate that analysis of methylation in
the DNA from peripheral circulation (fcDNA) can help in
determining prognosis or in predicting response to certain
types of treatment. Of more importance, perhaps, is that
since methylation is a reversible event, its modulation can
constitute a future therapeutic target.
Reversal of methylation status and, as such, the genetic
expression resulting from this mechanism, could cause a
recovery of function of those genes responsible for the
regulation of the normal cell cycle which, as a result of
an alteration in the methylation pattern, are abnormally
silenced. This could be of considerable interest because
such an easily measured analyte (ESR1 DNA methylation
in peripheral blood) can serve as biomarker, and prob-
able therapeutic target against breast cancer.
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